alpha-aminopyridine has been researched along with Carcinoma in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Bona, BJ; Moyer, ML; Nordeen, SK | 1 |
| Chang, RJ; Chang, SC; Chen, YT; Chiu, YL; Dong, JR; Hsu, CH; Hsu, FS; Huang, KH; Kuo, KL; Liao, SM; Lin, WC; Liu, SH; Yang, SP | 1 |
| Cao, J; Chen, X; Ge, J; Guo, X; Guo, Y; Li, L; Li, W; Liu, M; Liu, X; Shao, Y; Tian, L; Xu, L; Yang, Z; Zhang, J; Zhao, R | 1 |
| Chen, IC; Lu, YS; Yang, MH | 1 |
| Harrington, M | 1 |
| Kimura-Tsuchiya, R; Saji, S; Sasaki, E | 1 |
| Beijersbergen, RL; Bernards, R; Halonen, P; Leite de Oliveira, R; Lieftink, C; Šuštić, T; van de Ven, M; van den Heuvel, MM; van der Heijden, MS; Wang, L | 1 |
7 other study(ies) available for alpha-aminopyridine and Carcinoma
| Article | Year |
|---|---|
Modulation of glucocorticoid-regulated transcription by purines: novel characteristics and implications for tissue specificity of steroid responses.
Topics: 1-Methyl-3-isobutylxanthine; Aminopyridines; Animals; Carcinoma; Gene Expression Regulation; Glucocorticoids; Kinetics; Mammary Neoplasms, Experimental; Mice; Purines; Signal Transduction; Transcription, Genetic; Tumor Cells, Cultured | 1995 |
PR-619, a General Inhibitor of Deubiquitylating Enzymes, Diminishes Cisplatin Resistance in Urothelial Carcinoma Cells through the Suppression of c-Myc: An In Vitro and In Vivo Study.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cisplatin; Deubiquitinating Enzymes; Drug Resistance, Neoplasm; Humans; Mice, Nude; Thiocyanates; Ubiquitin Thiolesterase; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2021 |
Chidamide, a novel histone deacetylase inhibitor, inhibits laryngeal cancer progression in vitro and in vivo.
Topics: Aminopyridines; Animals; Apoptosis; Carcinoma; Cell Line, Tumor; Cell Proliferation; Histone Deacetylase Inhibitors; Humans; Laryngeal Neoplasms; Quality of Life | 2023 |
PI3K inhibitor provides durable response in metastatic metaplastic carcinoma of the breast: A hidden gem in the BELLE-4 study.
Topics: Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Female; Humans; Metaplasia; Morpholines; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Randomized Controlled Trials as Topic; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Mouse model to clarify ovarian clear-cell carcinoma.
Topics: Aminopyridines; Animals; Carcinoma; Class I Phosphatidylinositol 3-Kinases; Disease Models, Animal; DNA-Binding Proteins; Female; Humans; Mice; Morpholines; Nuclear Proteins; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Transcription Factors | 2015 |
Molecular diagnostics for precision medicine in breast cancer treatment: what does the future hold?
Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estradiol; Everolimus; Female; Fulvestrant; Humans; Molecular Targeted Therapy; Pathology, Molecular; Piperazines; Precision Medicine; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; TOR Serine-Threonine Kinases; Trastuzumab | 2016 |
A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Humans; Mice, Nude; Molecular Targeted Therapy; Morpholines; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Receptors, Fibroblast Growth Factor; RNA Interference; Signal Transduction; Time Factors; Transfection; Tumor Burden; Urinary Bladder Neoplasms; Urothelium; Xenograft Model Antitumor Assays | 2017 |